Meta-analysis of Shugan Jieyu Capsule for Depression in Patients with Coronary Heart Disease

Overview

Journal Medicine (Baltimore)

Specialty General Medicine

Date 2023 Sep 1

PMID 37653746

Authors

Zhen Liu

Chunhua Gu

Jian Lei

Affiliations

Soon will be listed here.

Abstract

Introduction: Shugan Jieyu Capsule (SGJYC) has been prescribed to treat primary and secondary depression; however, whether it can benefit depression of patients with coronary heart disease (CHD) remains controversial. This meta-analysis aimed to evaluate the efficacy and safety of SGJYC in treating depression in patients with CHD.

Patient Concerns: A total of 644 CHD patients with depression were selected from China National Knowledge Infrastructure, Wanfang, China Biomedical Database, MEDLINE, the Cochrane library from their inceptions until June, 2021.

Diagnosis: All patients with CHD or coronary artery disease were confirmed to suffer from depression based on recognized criteria.

Intervention: Patients were assigned randomly to receive SGJYC-based regimens or conventional antidepressants alone.

Outcomes: Meta-analysis of 6 studies showed that antidepressants (MD, 2.12; 95% confidence interval [CI], 0.73~3.50) or sertraline (MD, 2.15; 95%CI, 0.61~3.68) significantly alleviated depression level compared to SGJYC; however, SGJYC plus antihypertensive drugs (AHD) (MD, -8.33; 95%CI, -13.90 ~ -2.75) significantly improved depression symptoms compared to AHD. A significant difference in risk of adverse cardiac events (risk ratios [RR], 2.72; 95%CI, 1.07~6.94) between SGJYC and sertraline was detected in patients with simple CHD.

Conclusions: SGJYC has a poor effect on depressive symptoms, and the effect of combination with AHD is better than AHD but its efficacy and cardiac safety are inferior to antidepressants.

Citing Articles

Shugan Jieyu capsule effects on peripheral blood micro-124, micro-132, and brain-derived neurotrophic factor in patients with mild to moderate depression.

Zhang X, Liu Y, Tang H, Jiang F, Chen C, Wang T World J Psychiatry. 2024; 14(9):1354-1363.

PMID: 39319232 PMC: 11417661. DOI: 10.5498/wjp.v14.i9.1354.

Research Status and Trends of Traditional Chinese Medicine Therapeutic Formulae for Coronary Heart Disease Scientometrics Research.

Zhou M, Li J, Xiao X, Lim J, Tian Z, Wang D Int J Gen Med. 2024; 17:971-983.

PMID: 38495923 PMC: 10944307. DOI: 10.2147/IJGM.S450876.

References

Pu Z, Xia J, Xie W, He J . [Exploring the clinical characters of Shugan Jieyu capsule through text mining]. Zhongguo Zhong Yao Za Zhi. 2017; 42(17):3430-3433. DOI: 10.19540/j.cnki.cjcmm.20170710.002. View

Fan M, Guo D, Tian Y, Liu Y, Zhao J . Efficacy and safety of Shugan Jieyu capsule in the treatment of essential hypertension with insomnia, anxiety or depression: A protocol for systematic review and meta-analysis. Medicine (Baltimore). 2021; 100(8):e24856. PMC: 7909162. DOI: 10.1097/MD.0000000000024856. View

Wan X, Wang W, Liu J, Tong T . Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 2014; 14:135. PMC: 4383202. DOI: 10.1186/1471-2288-14-135. View

Tao J, Kong L, Fang M, Zhu Q, Zhang S, Zhang S . The efficacy of Tuina with herbal ointment for patients with post-stroke depression: study protocol for a randomized controlled trial. Trials. 2021; 22(1):504. PMC: 8320029. DOI: 10.1186/s13063-021-05469-1. View

Vaccarino V, Badimon L, Douglas Bremner J, Cenko E, Cubedo J, Dorobantu M . Depression and coronary heart disease: 2018 position paper of the ESC working group on coronary pathophysiology and microcirculation. Eur Heart J. 2019; 41(17):1687-1696. PMC: 10941327. DOI: 10.1093/eurheartj/ehy913. View

Kuhlmann S, Arolt V, Haverkamp W, Martus P, Strohle A, Waltenberger J . Prevalence, 12-Month Prognosis, and Clinical Management Need of Depression in Coronary Heart Disease Patients: A Prospective Cohort Study. Psychother Psychosom. 2019; 88(5):300-311. DOI: 10.1159/000501502. View

Liu W, Qin J . Clinical efficacy and safety of the Shugan Jieyu capsule in patients with acute myocardial infarction and depression. Int J Psychiatry Med. 2017; 51(6):534-543. DOI: 10.1177/0091217417696740. View

Fu J, Zhang Y, Wu R, Zheng Y, Zhang X, Yang M . Shuganjieyu capsule increases neurotrophic factor expression in a rat model of depression. Neural Regen Res. 2014; 9(5):489-97. PMC: 4153504. DOI: 10.4103/1673-5374.130067. View

Higgins J, Altman D, Gotzsche P, Juni P, Moher D, Oxman A . The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011; 343:d5928. PMC: 3196245. DOI: 10.1136/bmj.d5928. View

10.

Brok J, Thorlund K, Gluud C, Wetterslev J . Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses. J Clin Epidemiol. 2008; 61(8):763-9. DOI: 10.1016/j.jclinepi.2007.10.007. View

11.

Zhang M, Bai X . Shugan Jieyu Capsule in Post-Stroke Depression Treatment: From Molecules to Systems. Front Pharmacol. 2022; 13:821270. PMC: 8818889. DOI: 10.3389/fphar.2022.821270. View

12.

Yao G, Zhang X, Li J, Liu S, Li X, Liu P . Improving Depressive Symptoms of Post-stroke Depression Using the Shugan Jieyu Capsule: A Resting-State Functional Magnetic Resonance Imaging Study. Front Neurol. 2022; 13:860290. PMC: 9047823. DOI: 10.3389/fneur.2022.860290. View

13.

Biggerstaff B, Tweedie R . Incorporating variability in estimates of heterogeneity in the random effects model in meta-analysis. Stat Med. 1997; 16(7):753-68. DOI: 10.1002/(sici)1097-0258(19970415)16:7<753::aid-sim494>3.0.co;2-g. View

14.

. The prevalence of coronary heart disease in Type 2 diabetic patients in Italy: the DAI study. Diabet Med. 2004; 21(7):738-45. DOI: 10.1111/j.1464-5491.2004.01230.x. View

15.

de Blasio F, Blasio F, Berlingieri G, Bianco A, La Greca M, Franssen F . Evaluation of body composition in COPD patients using multifrequency bioelectrical impedance analysis. Int J Chron Obstruct Pulmon Dis. 2016; 11:2419-2426. PMC: 5053371. DOI: 10.2147/COPD.S110364. View

16.

DerSimonian R, Laird N . Meta-analysis in clinical trials. Control Clin Trials. 1986; 7(3):177-88. DOI: 10.1016/0197-2456(86)90046-2. View

17.

Yekehtaz H, Farokhnia M, Akhondzadeh S . Cardiovascular considerations in antidepressant therapy: an evidence-based review. J Tehran Heart Cent. 2015; 8(4):169-76. PMC: 4434967. View

18.

Feng L, Li L, Liu W, Yang J, Wang Q, Shi L . Prevalence of depression in myocardial infarction: A PRISMA-compliant meta-analysis. Medicine (Baltimore). 2019; 98(8):e14596. PMC: 6407970. DOI: 10.1097/MD.0000000000014596. View

19.

Meijer A, Conradi H, Bos E, Thombs B, van Melle J, de Jonge P . Prognostic association of depression following myocardial infarction with mortality and cardiovascular events: a meta-analysis of 25 years of research. Gen Hosp Psychiatry. 2011; 33(3):203-16. DOI: 10.1016/j.genhosppsych.2011.02.007. View

20.

Hagstrom E, Norlund F, Stebbins A, Armstrong P, Chiswell K, Granger C . Psychosocial stress and major cardiovascular events in patients with stable coronary heart disease. J Intern Med. 2017; 283(1):83-92. DOI: 10.1111/joim.12692. View